Krystal Biotech (KRYS)

Krystal Biotech (KRYS) Income Statement


Krystal Biotech Income Statement

Last quarter (Q3 2023), Krystal Biotech's total revenue was $8.60M, an increase of Infinity% from the same quarter last year. In Q3, Krystal Biotech's net income was $81.24M. See Krystal Biotech’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 8.60M-$ 0.00$ 0.00$ 0.00$ 0.00
Cost of Revenue
Gross Profit
$ 8.60M-----
Operating Expense
$ 108.92M$ 145.20M$ 68.28M$ 33.00M$ 22.08M$ 11.92M
Operating Income
$ -100.36M$ -145.20M$ -68.28M$ -33.00M$ -22.08M$ -11.92M
Net Non Operating Interest Income Expense
--$ -1.29M$ 832.00K$ 2.99M$ 1.03M
Other Income Expense
$ -100.00M-----
Pretax Income
$ -12.37M$ -139.97M$ -69.57M$ -32.17M$ -19.09M$ -10.89M
Tax Provision
-$ -10.44M----
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ 2.73M$ -139.97M$ -69.57M$ -32.17M$ -19.09M$ -10.89M
Basic EPS
$ -0.13$ -5.49$ -3.13$ -1.71$ -1.20$ -0.97
Diluted EPS
$ -0.22$ -5.49$ -3.13$ -1.71$ -1.20$ -0.97
Basic Average Shares
$ 80.41M$ 25.49M$ 22.20M$ 18.79M$ 15.90M$ 11.20M
Diluted Average Shares
$ 81.26M$ 25.49M$ 22.20M$ 18.79M$ 15.90M$ 11.20M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 108.92M$ 145.20M$ 68.28M$ 33.00M$ 22.08M$ 11.92M
Net Income From Continuing And Discontinued Operation
$ 2.24M$ -139.97M$ -69.57M$ -32.17M$ -19.09M$ -10.89M
Normalized Income
$ 28.80M-$ -69.57M$ -32.17M$ -19.09M$ -10.89M
Interest Expense
--$ 1.49M$ 0.00--
$ -12.37M$ -139.97M$ -68.08M$ -32.17M$ -22.08M$ -11.92M
$ -10.84M$ -135.96M$ -65.31M$ -30.32M$ -20.99M$ -11.78M
Currency in USD

Krystal Biotech Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis